From September 9 to September 13, Norroy first attended the 36th Annual Congress of the European Association of Nuclear Medicine (EANM) in 2023 in Vienna, Austria. The results of the latest clinical studies were presented during the conference in the form of four oral presentations and two posters, of which NY104 pipeline gave a special review at the conference. As China's original innovation nuclear medicine force, Norroy has attracted the attention of international nuclear medicine experts.

The 68Ga-NY104 IND application has been approved by FDA and is the world's first clinically approved small molecule positron emission tomography (PET) diagnostic tracer for kidney cancer. In the Ph0 clinical trials of nearly 100 subjects, 68Ga-NY104 has shown an incomparable advantage.

Dr. Wai-si Eng, Chief Technology Officer of Norroy, attended the meeting and gave a presentation on the clinical results of 68Ga/177Lu-NY108(NYM032). NY108(NYM032) is a new generation of integrated nuclear drug for prostate cancer diagnosis and treatment. The preliminary preclinical and clinical results suggest that it is expected to bring patients more accurate, safer, more effective and more economical treatment options with lower dose.

EANM is the most influential meeting in nuclear medicine and related fields, attracting more than 7,000 participants each year, including many of the world's top experts, researchers, industry professionals and so on. Nuoyu will be based in China, take globalization as its strategic development goal, represent China's original innovation force, and play a stronger voice for nuclear medicine to the world.